Alerts will be sent to your verified email
Verify EmailGUFICBIO
Gufic Biosciences
|
Sequent Scientific
|
Orchid Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
R&D as a % of Total Sales
|
0.83 % | 0.0 | n/a |
Financials
|
|||
5 yr Average ROE
|
25.05 % | 1.28 % | -4.13 % |
5yr average Equity Multiplier
|
2.22 | 2.12 | 1.73 |
5yr Average Asset Turnover Ratio
|
1.05 | 0.92 | 0.45 |
5yr Avg Net Profit Margin
|
10.9 % | 0.94 % | -7.02 % |
Price to Book
|
6.69 | 5.53 | 3.49 |
P/E
|
46.88 | 322.52 | 38.77 |
5yr Avg Cash Conversion Cycle
|
26.94 Days | 55.84 Days | 49.11 Days |
Inventory Days
|
66.86 Days | 76.26 Days | 112.59 Days |
Days Receivable
|
128.09 Days | 87.51 Days | 91.49 Days |
Days Payable
|
163.91 Days | 117.98 Days | 201.52 Days |
5yr Average Interest Coverage Ratio
|
13.1 | 2.31 | -0.51 |
5yr Avg ROCE
|
27.25 % | 7.29 % | 0.51 % |
5yr Avg Operating Profit Margin
|
18.45 % | 8.58 % | 10.69 % |
5 yr average Debt to Equity
|
0.51 | 0.5 | 0.49 |
5yr CAGR Net Profit
|
14.26 % | n/a | n/a |
5yr Average Return on Assets
|
11.52 % | 0.71 % | -1.77 % |
Shareholdings
|
|||
Promoter Holding
|
72.51 % | 52.61 % | 69.84 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-2.97 % | -0.41 % | -20.16 % |
Change in Mutual Fund Holding (3 Yrs)
|
2.36 % | 9.92 % | 16.34 % |
Gufic Biosciences
|
Sequent Scientific
|
Orchid Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|